U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840535) titled 'A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer' on Feb. 17.
Brief Summary: The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Prostate Cancer Metastatic Disease
PSA Level Greater Than 0.2
Intervention:
DRUG: [68Ga]Ga-OncoACP3
Patients receive a single intravenous bolus injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Philogen S.p.A.
Published by HT Digital Content Services with permission from Health Daily Digest....